Labs

D. Haydar Laboratory

About the Lab

The D. Haydar Laboratory works on designing effective, long-lasting, and safe cellular immunotherapies for childhood brain cancer. CAR T cell therapy is an innovative technology based on adoptive transfer of antigen-specific T cells engineered to elicit a clinically effective and specific immune response against tumor cells. Our aim is to investigate mechanisms responsible for the lack of CAR T cell efficacy in pediatric brain tumors using cutting-edge technologies and innovative animal models that recapitulate human disease and barriers for adoptive immunotherapies.

Featured Publications

  • cBAF complex components and MYC cooperate early in CD8+ T cell fate

    Guo, Ao, et al. Nature 607.7917:135-141 (2022)

  • T-Cell Immunotherapy for Pediatric High-Grade Gliomas: New Insights to Overcoming Therapeutic Challenges

    Haydar, Dalia, et al. Frontiers in Oncology 11 (2021)

  • Cell-surface antigen profiling of pediatric brain tumors: B7-H3 is consistently expressed and can be targeted via local or systemic CAR T-cell delivery

    Haydar, Dalia, et al. Neuro-Oncology 23.6:999-1011 (2021)

  • Proinflammatory cytokines promote TET2-mediated DNA demethylation during CD8 T cell effector differentiation

    Zebley, Caitlin C., et al. Cell reports 37.2:109796 (2021)

  • Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity

    Prinzing, Brooke, et al.  Science Translational Medicine 13.620:eabh0272 (2021)

  • Route of 41BB/41BBL costimulation determines effector function of B7-H3-CAR. CD28ζ T cells

    Nguyen, Phuong, et al. Molecular Therapy-Oncolytics 18:202-214 (2020)

  • Chimeric antigen receptor T-cell therapy in glioblastoma: charging the T cells to fight

    Land, Craig A., et al. Journal of translational medicine 18.1:1-13 (2020)

Related News

See All Related News